Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

Combination Product: Ravulizumab OBDS

[1] Ravulizumab (ravulizumab-cwvz)

[1] Ravulizumab (Ravulizumab, Ravulizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[1] 62 💬

2

[1] Ravulizumab (ravulizumab-cwvz)

[1] Ravulizumab (Ravulizumab, Ravulizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[7] 2, 11, 13, 50, 62, 66, 109 💬

Disease ID	Name
2	Amyotrophic lateral sclerosis
11	Myasthenia gravis
13	Multiple sclerosis/Neuromyelitis optica
50	Dermatomyositis
62	Paroxysmal nocturnal hemoglobinuria
66	IgA nephropathy
109	Atypical hemolytic uremic syndrome

3

ULTOMIRIS ™ (ravulizumab-cwvz)

[1] Ravulizumab (ravulizumab-cwvz)

[1] Ravulizumab (Ravulizumab, Ravulizumab) 💬

[1] C5 💬

[11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬

[1] 62 💬